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A number of members of the G protein-coupled receptor class of cell sur-
face receptors are ‘orphans’ with no known endogenous ligand. One of
these orphan receptors is GPR61; there are little data about its expression
in human cells and tissues. In this study, we investigated the post-transla-
tional modification of GPR61 by N-glycosylation at an identified consensus
N-glycosylation site (N12) and the impact of this modification upon the
subcellular expression of the protein. The N-glycosylation inhibitor tuni-
camycin reduced the apparent molecular weight of immunoreactivity asso-
ciated with myc-tagged GPR61 by 1–2 kDa, which was comparable to the
evident molecular weight of the myc-tagged N12S GPR61 mutant with dis-
rupted consensus N-glycosylation site. Analysis of GPR61 expression
demonstrated that tunicamycin treatment reduced considerably heterolo-
gous expression of GPR61 in the cell membrane despite the N12S GPR61
mutant being readily expressed at the cell surface. These results demon-
strate that GPR61 is subject to N-glycosylation but suggest this is not a
prerequisite for cell surface expression, although N-glycosylation of other
proteins may be important for cell membrane expression of GPR61.
Expression of GPR61 protein was demonstrated at the cellular level in
human hippocampus and human peripheral blood mononuclear cells. In
the latter, there was a significantly higher expression of GPR61 in the
Th17 cell subset in comparison with resting CD4+ cells, which may point
toward a potential role for the GPR61 receptor in autoimmune diseases.
This is the first report that GPR61 protein is subject to post-translational
modification and is expressed in immune cell subsets and the hippocampus.
These findings will help guide studies to investigate the function of GPR61.
G protein-coupled receptors (GPCRs) are the largest
family of cell surface receptors and are the therapeutic
targets for nearly a third of clinically marketed drugs [1],
yet a number of human GPCRs remain poorly under-
stood including lack of knowledge of their endogenous
orthosteric ligand. Included in these so-called orphan
receptors is GPR61 (other names: GPCR3, biogenic
amine receptor-like G protein-coupled receptor, BALGR),
which is predicted to be a 49-kDa GPCR that belongs to
orphan receptors class A [2,3].
Abbreviations
B cells, B lymphocytes; CA 1–4, Cornu Ammonis areas of hippocampus; DG, dentate gyrus; GPCR, G protein-coupled receptor; PBMCs,
peripheral blood mononuclear cells; T cells, T lymphocytes.
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The quaternary structure and function of this recep-
tor have not been revealed. The initial report identify-
ing the GPR61 clone indicated that the amino acid
sequence of GPR61 shares some degree of sequence
similarity (28–31%) with certain histamine, adrenergic,
serotonin, and dopamine receptors [2], although it was
later suggested that GPR61 might be better grouped
with melatonin receptors by phylogenetic clustering
[4]. GPR61 mRNA is expressed across a wide range of
tissues with brain, testis, and leukocytes having the
highest apparent levels of expression [2,5]. Of rele-
vance, recent immunohistochemistry (IHC) staining
revealed that the zona glomerulosa has the highest
expression of GPR61 within the human adrenal gland,
with a potential link to aldosterone synthesis [6].
The first study reporting a potential low-affinity
inverse agonist for GPR61 was published in 2003 [7];
5-(nonyloxy)-tryptamine (5-NOT) impacted a chimeric
receptor with high micromolar potency. Interestingly,
there is some evidence for autoregulation of the recep-
tor activity [8], its constitutive activity [9], although
one previous work was not supportive [10].
Knowledge about cellular and physiological functions
for GPR61 is inferred from studies with GPR61-knock-
out (ko) mice. These mice display elevated levels of liver
triacylglycerols, plasma leptin, and insulin [11], which
may underlie the greater fat mass and correlate with
lower levels of hypothalamic proopiomelanocortin and
brain-derived neurotropic factor mRNA. Such findings
forward the GPR61 receptor as a target to regulate body
weight and food intake and hence may provide a target
for antiobesity drugs. In addition, GPR61 has also been
proposed to play a role in aldosterone production [12].
Given the potential of the GPR61 receptor as a drug
target for therapeutic benefit, we have studied the poten-
tial importance of N-glycosylation of GPR61 protein –
the functions of many GPCRs are influenced by this
post-translational modification [13,14] – and also investi-
gated the presence of the protein in some human tissues.
Materials and methods
Cell culture and cloning
Wild-type GPR61 plasmid DNA (R&D Systems, Minneapo-
lis, MN, USA) was inserted into pCMV6-An-His-Myc vector
(OriGene, Rockville, MD, USA) using HindIII and XhoI
restriction enzymes (Fig. 1). The N12S mutant was generated
using Q5 site-directed mutagenesis kit (NEB, Ipswich, MA,
USA) by PCR DNA amplification with the following primers:
50-TCATCAGGGAGCTCTTCCACTTTG-30 and 50-CTGGG
GGATGGGTGAGGA-30 according to the manufacturer’s
instructions. Plasmid cDNA was then transformed into XL10
gold-competent cells (Stratagene, San Diego, CA, USA) and iso-
lated using Plasmid Maxi Kit (Qiagen, Hilden, Germany). The
identity of DNA was confirmed by DNA sequencing. The plas-
mid concentration was determined using NanoDrop 2000
(Thermo Fisher Scientific, Waltham, MA, USA).
Plasmid cDNA (10 lg) was transfected into ~ 90% conflu-
ent HEK293 cells of early passage (< 20, cells coming from our
laboratory’s repository) using Lipofectamine 2000 reagent
(Thermo Fisher Scientific), and stably transfected cells were
selected with geneticin (500 lgmL1; Thermo Fisher Scientific)
over a period of 4–5 weeks. The GPR61-expressing cells were
maintained in Dulbecco’s modified Eagles’ medium, supple-
mented with 10% (v/v) fetal bovine serum, 1% (v/v) penicillin/
streptomycin (10 000 UmL1 penicillin and 10 mgmL1
streptomycin), and geneticin (250 lgmL1). The cells were
maintained at 37 °C, 5% CO2, 95% relative humidity.
Antibodies to GPR61
Specificity of commercially available anti-GPR61 antibody
(sc-54599, SCT) was tested in flow cytometry and western
blot using recombinant HEK293 cells, and it was confirmed
that this antibody cannot be used to effectively assay for
GPR61 expression in these cells. GPR61 antisera were pro-
vided by A. Davenport, and it was shown that GPR61-
transfected cells have significantly higher staining levels in
flow cytometry than untransfected cells.
SDS/PAGE and western blotting
Cells were scraped off the culture flask and sonicated over wet
ice. Following the sonication, samples were resuspended in an
equal volume of 29 radioimmunoprecipitation assay buffer
(RIPA; Cell Signaling Technology, Danvers, MA, USA) and
appropriate volume of 29 urea sample buffer. No more than
30 lg of protein was loaded and run on 4–20% Tris/glycine
gels (Bio-Rad, Hercules, CA, USA, cat. 4561094). For each
gel, at least one molecular weight ladder was included (New
England Biolabs, Ipswich, MA, USA, cat. P7712). Proteins
were transferred onto PVDF membranes, which were then
blocked in 10% nonfat milk (Marvel) for 2 h at room tempera-
ture. Membranes were incubated in 1 : 3000 anti-myc (Cell
Signaling Technology) or 1 : 3000 anti-GAPDH (Abcam,
Cambridge, UK) in 5% nonfat milk overnight at 4 °C before
washing at room temperature. Membranes were incubated
subsequently in anti-mouse or anti-rabbit HRP-linked sec-
ondary antibody (Cell Signaling Technology) in 5% nonfat
milk in wash buffer at room temperature for 2 h. Membranes
were washed and then incubated in ECL reagent for 5 min.
The membrane was subsequently exposed to film and devel-
oped. Alternatively, the membrane was developed using Che-
miDoc MP system imager (Bio-Rad) that also allows for the
subsequent quantification of chemiluminescent bands. Images
acquired using ChemiDoc MP were analyzed in IMAGE LAB
5.2.1 software (Bio-Rad).
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Immunocytochemistry
Cells were seeded at a density of 50 000 cells on poly-D-lysine-
coated coverslips and cultured for 18 h at 37 °C. The cells
were then washed in PBS and fixed with 2% formaldehyde
solution (Sigma Aldrich, St Louis, MO, USA, cat. F8775) for
15 min at room temperature and protected from light. After
washing, for staining intracellular proteins, cells were perme-
abilized with 0.3% Triton X-100 (Sigma Aldrich, cat. X100)
in PBS for 20 min at room temperature. The cells were then
washed with PBS and blocked in 10% FBS in PBS (blocking
buffer) for 1 h. After the blocking step, primary antibody
solution (1 : 3000 anti-myc or 1 : 2000 GPR61 antisera) in
blocking buffer was added and incubated overnight at 4 °C.
On the following day, primary antibody was removed by
washing with PBS. Secondary antibody solution (1 : 1000 flu-
orochrome-conjugated secondary antibody; Thermo Fisher
Scientific) in blocking buffer was then added and incubated
for 3 h at room temperature. Cells were then washed in PBS.
In the experiments in which myc-tagged GPR61 was used to
stain extracellularly and intracellularly, cells were permeabi-
lized on the second day after the first application of the sec-
ondary antibody. The procedure was then repeated: Cells
were incubated overnight at 4 °C in a primary antibody solu-
tion. On the following day, the cells were washed and a differ-
ent secondary antibody conjugated to a different
fluorochrome at the same concentration was added in block-
ing buffer and left to incubate for 3 h at room temperature.
After the incubation with the secondary antibody solution,
the cells were washed with PBS. The coverslips containing the
cells were then mounted on microscope slides with Vecta-
Shield Hardset mounting medium containing DAPI (Vector
Laboratories, Burlingame, CA, USA, cat. H-1500). Images
were captured on the same day using Zeiss LSM Meta 510
confocal microscope and analyzed in LSM IMAGE BROWSER soft-
ware (Zeiss, Oberkochen, Germany).
Myc immunoreactivity by flow cytometry
HEK293 cells stably expressing His-myc-tagged GPR61 and
untransfected HEK293 cells were used. Some cells were treated
with 1.0 lgmL1 tunicamycin (Sigma Aldrich) for 48 h to
inhibit the N-glycosylation. Following the treatment, medium
was aspirated from the cells and the cells were washed in PBS.
The cells were then detached from the flask by the addition of
1 mM EDTA PBS and were left at 4 °C for 10 min. The cells
were transferred to complete DMEM and centrifuged twice at
400 g for 5 min. The supernatant was discarded and the cells
were resuspended in 0.5% BSA/PBS. The cells were resus-
pended in 1 : 500 mouse anti-myc antibody in 0.5% BSA/PBS
and incubated for 1 h at 4 °C. The cells were then washed
twice by centrifugation and resuspended in 1 : 200 goat anti-
mouse PE (Abcam) in 0.5% BSA in PBS. The cells were incu-
bated for 30 min at room temperature. The cells were then
washed twice by centrifugation before resuspension in 0.5%
BSA/PBS and immediately assayed using ADP Cyan flow
cytometer (Beckman Coulter, Brea, CA, USA).
Hippocampus tissue samples and
immunohistochemistry
Human formalin-fixed, paraffin-embedded hippocampal
samples were obtained from the Medical Research Council,
Edinburgh Brain and Tissue Bank (University of Edin-
burgh, Edinburgh, UK). The donors (aged 20–40, post-
mortem index 36–77 h) were free from neurological or
psychological conditions. The study was approved by the
University of Birmingham Ethics Committee.
The immunohistochemistry staining was conducted as
previously described by Brady et al. [15].
Isolation of human peripheral blood
mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from whole blood from healthy donors or from leukocyte
reduced system (LRS) cones using Ficoll–Paque (GE
Healthcare, Little Chalfont, UK). In some experiments,
cells were stimulated in the presence of PHA-L (5 lgmL1;
Roche, Basel, Switzerland) for 24 h.
RNA isolation from human hippocampus and
PBMCs
Total RNA was isolated from human PBMCs using QIA-
GEN RNeasy Mini Kit according to the manufacturer’s
instructions with DNase treatment included. RNA concen-
tration and purity were measured on NanoDrop 2000, and
RNA was stored at 80 °C prior to the experiments.
Real-time PCR analysis of GPR61 expression in
human PBMCs
The Precision OneStep qRT-PCR mastermix, b-actin, and
GPR61 primers were obtained from PrimerDesign. The
GPR61 primer sequences were as follows: 50-
CTTTCGAATCCCAGGCCAGA-30 (forward primer) and
50-GCAGGACGGAGGTAGCTG-30 (reverse primer).
GPR61 expression by PBMCs assessed by flow
cytometry
PBMCs were stained with a panel of antibodies specific for cell
surface markers (mouse anti-human CD4, CD8, CD14, and
CD19; eBioscience, San Diego, CA, USA) for 20 min at 4 °C
in 10% FcR blocker (Miltenyi, Bergish Gladbach, Germany).
The cells were then washed twice, fixed in Cytofix/Cytoperm
(BD) for 15 min at 4 °C, and permeabilized by washing in
Perm buffer (Becton Dickinson, Franklin Lakes, NJ, USA)
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before being stained with GPR61 antisera or control preim-
mune sera for 30 min at 4 °C. The cells were then washed
twice and stained with AlexaFluor647-conjugated anti-goat
antibody (1 : 2000; Thermo Fisher Scientific). The cells were
washed twice and assayed on ADP Cyan flow cytometer.
For the assessment of GPR61 expression in IFN-c+ and
IL-17+ cells, PBMCs were stimulated for 24 h with
5 lgmL1 phytohemagglutinin-M at 37 °C. After 24 h, the
plate was centrifuged and the cells were restimulated
with 50 ngmL1 phorbol 12-myristate-13-acetate and
Fig. 1. Amino acid sequence of the mature human recombinant GPR61 protein, highlighting the His-tag (in blue), myc-tag (in red), the
beginning of the native sequence (methionine in orange), and the potential N-glycosylation site (in green).
Fig. 2. (A) Prevention of N-glycosylation of GPR61 by tunicamycin reduces the molecular weight of the predominantmyc-immunoreactive species
arising from stable expression of the nonmutated myc-tagged GPR61. (B) The consensus N-glycosylation sequence at N12 was disrupted by
mutagenesis (N12S) with the arising myc-immunoreactive species displaying a lower apparent molecular weight compared with the nonmutated
protein, and furthermore, the N12S mutant apparent molecular weight was unaffected by tunicamycin treatment. Data presented are from a
single representative experiment, which was repeated at least five times with similar results. GAPDH was used as a loading control.
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750 ngmL1 ionomycin in the presence of 0.5 lL per well
GolgiStop for 3 h at 37 °C. After 3 h, the cells were
washed twice by centrifugation. Cells were stained for sur-
face markers as above. Cells were then fixed and incubated
for 15 min at 4 °C in the dark. The cells were then cen-
trifuged twice in 19 Perm/Wash buffer. The cells were
stained with anti-GPR61, anti-IFN-c, and anti-IL-17 anti-
bodies for 20 min at 4 °C. The cells were centrifuged twice
and stained with the AlexaFluor647-conjugated anti-goat
antibody. The cells were washed twice and assayed on
ADP Cyan flow cytometer.
Statistical analysis
Statistical analysis was performed using PRISM 6 (Graph-
Pad, La Jolla, CA, USA).
Results
SDS/PAGE/western blotting
SDS/PAGE separation of lysates of HEK293 stably
expressing nonmutated and N12S mutant myc-tagged
Fig. 3. Effect of tunicamycin treatment (48 h) on the cellular localization of GPR61 immunoreactivity in HEK293 stably transfected with
nonmutated myc-GPR61. (A) Upper panel: Immunocytochemical detection of myc immunoreactivity allowed detection of the nonmutated
GPR61 in unpermeabilized cells indicating protein expression in the cell membrane (red immunofluorescence). Subsequent permeabilization
of cells followed by re-immunolabeling allowed visualization of myc-immunoreactive protein expressed throughout the cell (green
immunofluorescence). DAPI stain (blue fluorescence) was used to visualize the cell nuclei. When the cell images were combined,
immunoreactive protein expressed in the cell membrane appears yellow, whereas intracellular immunoreactive protein appears green.
Treatment of cells with tunicamycin (1.0 lgmL1, 48 h) resulted in the reduced level of cell membrane myc immunoreactivity shown as
reduced levels of red staining. Lower panel: The same as in the upper panel but the intracellular staining following the permeabilization was
performed using anti-GPR61 sera and the resulting immunoreactivity appears green. The scale bar = 20 lm. Cells are representative within
a population with independent experiments repeated four times. (B) Upper panel: Immunocytochemical detection of myc immunoreactivity
allowed detection of the N12S GPR61 in unpermeabilized cells indicating protein expression in the cell membrane (red
immunofluorescence). Subsequent permeabilization of cells followed by re-immunolabeling allowed visualization of myc-immunoreactive
protein expressed throughout the cell (green immunofluorescence). DAPI stain (blue fluorescence) was used to visualize the cell nuclei.
When the cell images were combined, immunoreactive protein expressed in the cell membrane appears yellow, whereas intracellular
immunoreactive protein appears green. Treatment of the cells with tunicamycin (1.0 lgmL1, 48 h) resulted in the reduced level of cell
membrane myc immunoreactivity shown as reduced levels of red staining. Lower panel: The same as in the upper panel but the
intracellular staining following the permeabilization was performed using anti-GPR61 sera, and the resulting immunoreactivity appears green.
The scale bar = 20 lm. Cells are representative within a population with independent experiments repeated four times.
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GPR61 identified bands of immunoreactivity consis-
tent with the size of the predicted molecular weight of
the myc-tagged GPR61 receptor ~ 53 kDa (Fig. 2).
The stably transfected cells also gave rise to a sec-
ondary band at about 110 kDa, which may suggest
the formation of a dimer. Addition of tunicamycin
(1.0 lgmL1) to the cell culture medium for 48 h
reduced consistently the apparent molecular weight of
resulting myc-tagged GPR61 immunoreactivity by
1–2 kDa (Fig. 2), which was not apparent for the con-
trol protein GAPDH. This was further investigated by
the mutation of the predicted N-glycosylation site in
the N terminus of the myc-tagged GPR61 (N12),
which also resulted in the arising protein having a
reduced molecular weight of the predominant
immunoreactive species by 1–2 kDa compared with
the nonmutated protein. Tunicamycin-treated myc-
tagged GPR61 and myc-tagged N12S cell lysates
showed the same myc immunoreactivity pattern. These
results indicate that the myc-tagged GPR61 is N-glyco-
sylated.
Immunocytochemistry
Immunocytochemical studies on the transfected fixed
HEK293 performed with either anti-myc or anti-
GPR61 sera confirmed that myc-tagged GPR61 is
expressed both at the surface and inside the cells
(Fig. 3A,B). Cells treated with tunicamycin displayed
considerably reduced levels of myc-tagged GPR61
immunoreactivity when the cells were stained with anti-
myc antibody before permeabilization with no apparent
difference in the intracellular staining between treated
and untreated cells. When the N-glycosylation site of
myc-tagged GPR61 was disrupted (N12S), the staining
corresponding to extracellular epitope in the mutant
was similar to that of the nonmutated protein. How-
ever, following the tunicamycin treatment, the myc-
tagged N12S also showed markedly reduced levels of
surface myc staining, when compared with untreated
cells. These results point toward the lack of a direct
role for N-glycosylation of the myc-tagged GPR61 pro-
tein in the cell membrane trafficking of this protein.
Fig. 4. Tunicamycin (T+) reduces
membrane expression of nonmutated and
N12S mutant myc-tagged GPR61 in stably
transfected HEK293 cells. (A) Flow
cytometry plots (representative from five
independent experiments) showing the
reduced cell surface expression of myc-
tagged GPR61 in nonmutated (left plot)
and N12S mutant (right plot)-transfected
cells. Myc immunoreactivity of the cells
untreated with tunicamycin is represented
in red. Treatment with tunicamycin (blue)
causes a decrease in the membrane myc
immunoreactivity, indicating the lower
levels of cell membrane expression of
GPR61. The nonspecific
immunofluorescence was determined by
staining with the secondary antibody only,
under the same conditions (B) Median
fluorescence intensity (in arbitrary units,
a.u.) of extracellular myc immunoreactivity
shown as mean MFI  SEM (n = 5).
Tunicamycin reduces the level of
membrane GPR61 expression by ~ 40% in
nonmutated and N12S mutant GPR61-
stably expressing cells; *P < 0.05 (paired
t-test, analyzed for wt vs. wt T+, and
N12S vs. N12S T+).
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Under the same conditions, no immunofluorescence
was detected when preimmune sera replaced the pri-
mary sera (data not shown). The distribution of intra-
cellular staining revealed by either myc antibody or the
anti-GPR61 antibody was near identical, indicating
that these antibodies target the same protein.
Flow cytometry
Flow cytometric analysis of expression of myc-tagged
GPR61 and N12S in the transfected HEK293 cells
gave comparable results to immunocytochemistry
(Fig. 4A) but allowed better quantification of the
immunoreactivity. As opposed to the
immunocytochemical method, nonfixed cells were used
in order to minimize the risk of cell permeabilization
and prevent any intracellular staining. Using flow
cytometry, we have demonstrated that both nonmu-
tated and N12S forms of GPR61 were transported to
the cell membrane and their cell membrane expression
was reduced by approximately 40% following tuni-
camycin treatment (Fig. 4B).
Expression of GPR61 in human hippocampus
GPR61 immunoreactivity was detected at different
levels across hippocampal subfields (Fig. 5A–C). The
GPR61 protein was relatively highly expressed in cells
Fig. 5. GPR61 protein expression in human hippocampal subfields (n = 3, representative result of five different experiments). (A) GPR61
protein immunoreactivity with posthematoxylin counterstain. (B) Histological staining and the localization of the selected immunoreactivity
signals. (C) No primary antibody. (D) GPR61 preimmune sera. Scale bar = 20 lm, 100 lm.
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with the morphology of pyramidal neurons within sub-
fields CA1, CA2, and CA3 of the hippocampus, and
at lower levels in the granule cells of the dentate gyrus
(DG) and large neurons in CA4 subfield with the mor-
phology of GABAergic interneurons (Fig. 5A).
Immunoreactivity was not apparent when preimmune
sera exchanged the anti-GPR61 sera.
Expression of GPR61 in immune cells
GPR61 mRNA expression was evident in human
PBMCs with no real change in expression following
activation of the cells with PHA (DCt = 28.52 and
29.93, respectively, Fig. 6). GPR61 expression was
quantified by flow cytometry and was evident in all the
investigated cell subsets at similar levels (Fig. 7B–E).
In this study, we measured the expression of GPR61
receptor in CD4+ Th1 and Th17 cells and IFN-c-produ-
cing CD8+ cells. Specificity of the GPR61 antisera was
tested using recombinant HEK293 cells (Fig. 7A). Fol-
lowing the intracellular staining, GPR61 receptor expres-
sion was apparent in resting CD4+ and CD8+, stimulated
Th1 CD4+, effector CD8+ producing IFN-c and CD4+
Th17 cells withCD4+Th17 expressing significantly higher
levels of GPR61 than resting and Th1 cells (Fig. 8).
Discussion
GPR61 is an orphan GPCR with little information
concerning a role and very few published reports of
protein expression patterns. GPR61 mRNA expression
is relatively high in brain, leukocytes, and testis [2].
In this work, we have assessed the impact of N-gly-
cosylation on the cellular expression of this GPCR in
the stably transfected HEK293 cells. N-glycosylation
has been shown to have a major role in cell trafficking
and protein folding [16]. By the use of the N-glycosyla-
tion inhibitor, tunicamycin, and also the generation of
a non-N-glycosylated mutant, N12S GPR61, it was
evident that GPR61, when expressed in human cells, is
prone to N-glycosylation. However, our results also
indicate that while N-glycosylation of GPR61 is not
required for insertion into the cell membrane, per se,
nonselective inhibition of all N-glycosylation does pre-
vent GPR61 insertion into the cell membrane, suggest-
ing that N-glycosylated ‘chaperone’ proteins support
GR61 membrane trafficking, which become nonfunc-
tional when N-glycosylation is inhibited. Given the dif-
ficulty in identifying a functional activity for GPR61,
it would be tempting to speculate that the receptor
may function as a heterodimer and the delivery of the
heteromeric dimer to the cell membrane was dependent
on N-glycosylation of GPR61’s partner GPCR. One of
the potential candidates has been forwarder in the
most recent paper in which it was suggested that
GPR61 and also other members of its cluster, GPR62
and GPR135, may form a heterodimer with melatonin
MT2 receptor upon overexpressing both receptors [9].
The fact that GPR61 is subject to N-glycosylation
shows that it undergoes the same processes as many
other GPCRs [14]. The impact of N-glycosylation on a
membrane expression and a structure of ligand-binding
domain has been shown for several GPCRs, with the
examples including 5-HT5A [17], b2-adrenergic [18],
AT1 angiotensin [14], or B2-bradykinin [19].
There are a number of GPCR-interacting proteins
that, for example, influence the surface trafficking and
receptor signaling, and belong predominantly to heat
shock protein (Hsp), RAMP, and PDZ-domain fami-
lies. Some of these interacting proteins (e.g., RAMP2)
are subject to N-glycosylation [20]. Presumably, other
components of the machinery that are active in GPR61
cell membrane trafficking can also be impacted.
In order to be able to predict potential cellular func-
tions of GPR61, we have investigated expression in
human native tissues and cells with cellular resolution;
previous reports of GPR61 expression merely reported
expression by PCR, which showed relatively high
levels of GPR61 mRNA in human brain, leukocytes,
and testis [2]. Similarly, GPR61 mRNA expression
was found to be at relatively high or moderate levels
in mouse CNS (hypothalamus, olfactory bulb, stria-
tum, and hippocampus) and testis [21].
Fig. 6. mRNA GPC61 expression in the resting and stimulated
(PHA 5 lgmL1, 24 h) human PBMCs. b-Actin was used as
housekeeping gene. Data represented as mean  SEM from three
independent experiments.
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In this study, we have used two antibodies – a goat
polyclonal antibody that recognizes the C terminus
(H-Cys-Ser-Asp-Ser-Tyr-Leu-Arg-Pro-Ala-Ala-Ser-Pro-
Arg-Leu-Glu-Ser-OH) of GPR61 protein and a mouse
monoclonal antibody recognizing myc-tag added to the
N terminus of the GPR61 receptor – to study the
expression of native and myc-tagged GPR61 protein,
respectively. In this study, we show that these two anti-
bodies work effectively in immunocytochemistry and
flow cytometry assays. Immunocytochemical staining
of myc-tagged GPR61-transfected HEK293 cells
demonstrated that these two antibodies indeed target
the same protein. Additionally, the anti-myc antibody
was used in western blot studies where the polyclonal
goat antibody targeting the native protein failed to give
satisfactory results.
GPR61 protein expression was evident in the human
hippocampus; hippocampal GPR61 immunoreactivity
was widely expressed in the hippocampus at differing
levels. Strong immunoreactivity signals were evident in
the CA1, CA2, and CA3 subfields of the hippocampus
associated with cells often displaying the morphology
of pyramidal neurons. More moderate expression was
detected in the DG and CA4 subfields. Hippocampal
GPR61 expression in the hippocampus, particularly
when associated with pyramidal neurons, suggests an
involvement of this receptor in higher brain functions,
such as learning, memory, and cognition [22,23].
Our study also revealed that human PBMCs express
GPR61 protein (and also confirming the expression of
mRNA from our studies and reports in the literature;
[2]). We subsequently investigated subsets of human
Fig. 7. GPR61 protein immunoreactivity in
human PBMCs. (A) Specificity of GPR61
antisera was tested on HEK293 stably
expressing myc-GPR61. Blue –
untransfected HEK293 cells stained with
preimmune sera; orange – untransfected
HEK293 stained with GPR61 antisera;
green – HEK293 cells expressing myc-
GPR61 stained with preimmune sera; red
– HEK293 cells stably expressing myc-
GPR61 stained with GPR61 antisera. (B)
CD4+ T cells, (C) CD8+ T cells, (D) CD19+
B cells, (E) CD14+ monocytes. PBMCs
were isolated from healthy donors and
stained with cell surface markers specific
for each subset. Cells were then
permeabilized and the GPR61
immunoreactivity was assessed by
staining with GPR61 antisera (blue) or
preimmune control serum (red). The figure
shows a representative example from
three independent experiments.
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PBMCs using flow cytometry and demonstrated expres-
sion in the CD4+, CD8+, CD14+, and CD19+ cell subsets
isolated from blood from healthy volunteers, although
these subsets appeared to express similar levels of the
receptor. Examples of other relatively uniformly
expressed membrane receptors in leukocytes include
b-adrenergic and serotoninergic receptors [24]. GPCRs
can play a major role in functioning and the development
of immune responses, and many GPCRs have been
reported to take part in transcriptional regulation [25].
Perhaps more interestingly, within the CD4+ subset,
expression of GPR61 was higher in Th17 cells com-
pared to Th1 cells and significantly higher than in rest-
ing CD4+ T cells. Th17 cells have been intensively
studied in recent years since their discovery in early
2000s. These cells are a lineage of CD4+ T cell that
produces IL-17 and appears to have a pathophysiolog-
ical role in certain inflammatory diseases (e.g., multiple
sclerosis, rheumatoid arthritis, psoriasis). It has been
demonstrated that a shift from Th1 to Th17 phenotype
may be modified by GPCRs [26]. On the other hand,
antagonizing another GPCR – EP4 receptor for E2
prostaglandin – inhibited Th17 expansion and was
reported as effective in contact hypersensitivity, EAE,
and arthritis models [27,28]. Given the lack of reports
about physiological effects mediated by GPR61, a
potential role in Th17-dependent immunity and
autoimmunity may warrant further investigation.
To conclude, we are reporting for the first time that
GPR61 protein is subject to N-glycosylation, which is
consistent with many other GPCRs. In addition, this
membrane GPCR is expressed in the human brain
(hippocampus) and in T cells, B cells, and monocytes
with higher levels of protein expression in IL17-produ-
cing CD4+ T cells; such expression may help in the
search for cellular functions mediated by this receptor,
which may forward the receptor as a potential thera-
peutic target.
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